Skip to content
HabitSeek
Back to results

Choose whole grains over refined grains

Picking the wholegrain version of the grain foods you already eat — wholemeal or wholegrain bread, oats, brown rice, wholewheat pasta — instead of the refined versions.

At a glance

  • Evidence: Each additional 90 g a day of wholegrain intake was associated with 17 percent lower all-cause mortality and 22 percent lower cardiovascular disease across 45 prospective studies.Death from any cause and incident cardiovascular disease · Moderate certainty · Observational association
  • What’s uncertain: Disease estimates are observational; wholegrain eaters differ in other behaviours, so changing grains is not a tested mortality intervention.
  • First step: Change the grain in meals you already eat rather than adding new foods: wholegrain or wholemeal bread, oats at breakfast, brown or wholegrain rice, wholewheat pasta.
  • Before you try it: Coeliac disease and wheat allergy limit suitable grains; choose appropriate gluten-free options and increase fibre gradually. All precautions
Read the full takeaway

Cohort evidence

This is a food swap with unusually deep observational support. Across 45 prospective studies, each additional 90 g a day of wholegrains was associated with 17 percent lower all-cause mortality and 22 percent lower cardiovascular disease, and separate syntheses found lower type 2 diabetes and colorectal cancer risk.

Randomized trials

The crucial qualification is what happens when the same substitution is tested experimentally: 25 randomised trials lasting 2 to 16 weeks improved total cholesterol, LDL cholesterol, HbA1c and C-reactive protein, but the review's GRADE conclusion was that there is insufficient evidence to recommend wholegrains over refined grains for the prevention and treatment of cardiovascular disease. So the honest position is that the disease outcomes are associative and the trial evidence covers risk factors only.

Whole foods and fibre

Note also that this is a whole-food choice, not a fibre supplement: the fibre entry covers total fibre intake and the soluble-fibre entry covers viscous fibre for LDL, and the wholegrain effect is larger and broader than its fibre content alone would predict.

A homemade whole-grain loaf of breadDiscussed byChristopher GardnerView statements ↓
NutritionLong-term healthUnder 10 min · Easy · Low
Reviewed Sep 23, 2026
Save

Scientific evidence

What the research shows

Outcome assessments based on research, including its uncertainties and limitations.

Death from any cause and incident cardiovascular disease

Finding: Benefit supportedCertainty: Moderatestudies found a benefit from doing this

Evidence basis: observational studies (association, not proof of cause)

Each additional 90 g a day of wholegrain intake was associated with 17 percent lower all-cause mortality and 22 percent lower cardiovascular disease across 45 prospective studies.

Population: Adults in prospective cohort studies: 45 studies (64 publications) in the dose-response synthesis, and 20 cohorts contributing 2,282,603 participants and 191,979 deaths over follow-up of 5.5 to 26 years in the second synthesis.

Research details

Summary

In a systematic review and dose-response meta-analysis of 45 prospective studies (64 publications), the summary relative risk per 90 g/day increase in wholegrain intake was 0.81 (95% CI 0.75 to 0.87; I²=9%) for coronary heart disease, 0.88 (95% CI 0.75 to 1.03; I²=56%) for stroke and 0.78 (95% CI 0.73 to 0.85; I²=40%) for cardiovascular disease, with similar results whether the outcome was incidence or mortality. For mortality the relative risks were 0.83 (95% CI 0.77 to 0.90; I²=83%) for all causes and 0.85 (95% CI 0.80 to 0.91; I²=37%) for total cancer, and reductions in risk were observed up to an intake of 210-225 g/day. An independent synthesis of 20 prospective cohorts with 2,282,603 participants and 191,979 deaths reported a pooled relative risk for all-cause mortality of 0.83 (95% CI 0.79 to 0.88) for an increase of 3 servings of total wholegrains a day (90 g/day), and 0.84 (95% CI 0.76 to 0.93) for cardiovascular disease mortality. Intakes of whole grain bread, whole grain breakfast cereals and added bran were also associated with reduced risk, but there was little evidence of an association with refined grains, white rice or total grains.

Why this certainty

Rated Moderate. The direction is consistent across independent syntheses with very large participant numbers, a dose-response gradient is present, and the specificity of the finding to wholegrains rather than refined grains or total grains argues against pure confounding by general health behaviour. Certainty is held below Strong because the outcome data are entirely observational, exposure is self-reported, and heterogeneity for all-cause mortality is high, so the causal effect of the swap on an individual's risk is smaller and less certain than the pooled numbers imply.

Limitations

All of these estimates are observational, so they describe who developed disease rather than what happens when a person changes their diet, and people who choose wholegrains differ in income, education, smoking and overall diet quality in ways that adjustment cannot fully remove. Heterogeneity was substantial for all-cause mortality (I²=83%) and moderate for stroke and cardiovascular disease, so the pooled figures conceal genuinely different study results. Intake was estimated by food-frequency questionnaire, which misclassifies wholegrain consumption, and the association with refined grains was close to null rather than clearly harmful. The dose-response gradient flattens rather than reverses, so the very high intakes at the top of the range rest on few studies.

Effect estimate

All-cause mortality relative risk 0.83 (95% CI 0.77 to 0.90) and cardiovascular disease relative risk 0.78 (95% CI 0.73 to 0.85) per 90 g/day increase in wholegrain intake.

Sources for this outcome:

Incident type 2 diabetes and colorectal cancer

Finding: Benefit supportedCertainty: Moderatestudies found a benefit from doing this

Evidence basis: observational studies (association, not proof of cause)

Higher wholegrain intake was associated with 32 percent lower type 2 diabetes risk and 17 percent lower colorectal cancer risk per increment, while refined grains showed no association.

Population: Adults in prospective cohort studies: 16 cohorts for the type 2 diabetes dose-response analysis, 25 prospective studies for the colorectal cancer analysis, and 23 published meta-analyses of observational studies in the umbrella review.

Research details

Summary

A dose-response meta-analysis of 16 cohort studies found a summary relative risk for type 2 diabetes of 0.68 (95% CI 0.58 to 0.81; I²=82%, n=10) per 3 servings a day of wholegrains, against 0.95 (95% CI 0.88 to 1.04; I²=53%, n=6) for refined grains, with a non-linear association for wholegrains and inverse associations for whole grain bread, whole grain cereals, wheat bran and brown rice. In a separate dose-response meta-analysis of 25 prospective studies, the summary relative risk of colorectal cancer for an increment of three servings of wholegrains a day (n=6) was 0.83 (95% CI 0.78 to 0.89; I²=18%), and a large cohort-plus-review analysis of bran and germ found the type 2 diabetes association was stronger for bran than for germ. An umbrella review of 23 meta-analyses of observational studies concluded there was convincing evidence of an inverse association between wholegrain consumption and risk of type-2 diabetes and colorectal cancer.

Why this certainty

Rated Moderate. Two independent syntheses agree on the direction for type 2 diabetes, the colorectal cancer estimate is precise with low heterogeneity, and an umbrella review applying pre-selected criteria graded the diabetes and colorectal cancer associations as convincing, which is a stronger endorsement than the underlying cohorts alone would earn. Certainty is not higher because every estimate is observational, the diabetes result is heterogeneous, and there is no randomised trial with diabetes or cancer incidence as an endpoint, and the largest crossover trial found no effect on glucose homeostasis or the microbiome despite compliance-verified wholegrain intake, so the randomised evidence speaks to risk factors rather than to disease.

Limitations

These are associations, and the type 2 diabetes pooling showed high heterogeneity (I²=82%), which means the individual cohort results differ more than chance would explain. Wholegrain intake is self-reported by questionnaire, and people who eat more wholegrains also tend to weigh less, smoke less and eat more fruit and vegetables, all of which raise diabetes and cancer risk independently. Several subtype analyses rested on few studies, and the same umbrella review that graded the diabetes and colorectal cancer findings convincing also flagged a possible increased risk of prostate cancer with higher wholegrain intake, which has not been explained and argues against reading the evidence as uniformly favourable. The one large randomised crossover trial with an objective compliance biomarker complicates the mechanistic reading of the trials: despite a compliance-verified wholegrain intake of 179 g/day over eight weeks, it reported that wholegrain did not significantly alter glucose homeostasis and did not induce major changes in the faecal microbiome, and its reduction in body weight was consistent with a reduction in energy intake rather than a direct metabolic effect.

Effect estimate

Type 2 diabetes relative risk 0.68 (95% CI 0.58 to 0.81) per 3 servings/day of wholegrains; colorectal cancer relative risk 0.83 (95% CI 0.78 to 0.89) per 3 servings/day of wholegrains.

Sources for this outcome:

What people say

Who discusses this?

Public statements, with positions specific to each source and topic. These views do not determine the scientific evidence assessment.

What the research shows ↑

Practical steps and precautions

How to try it

  1. Change the grain in meals you already eat rather than adding new foods: wholegrain or wholemeal bread, oats at breakfast, brown or wholegrain rice, wholewheat pasta.
  2. Aim for roughly three servings a day as a practical target — 90 g of wholegrain food, equivalent to about two slices of wholegrain bread plus one bowl of wholegrain cereal — because that is the increment at which the pooled cohort estimates were calculated.
  3. Read the label rather than the colour: look for a wholegrain or wholemeal flour as the first ingredient, since brown-coloured bread and 'wheat' bread are often mostly refined flour.
  4. Check the fibre figure on the label as a quick proxy; a genuinely wholegrain bread usually carries several grams of fibre per slice, which is the part of the grain that refined milling removes.

Precautions

  • Increase wholegrain intake gradually over a few weeks. Sudden large increases in cereal fibre commonly cause bloating, wind and cramping, and these settle better with a slower change.
  • If you have irritable bowel syndrome or another condition affected by fermentable carbohydrate, the wholegrain you tolerate matters more than the category: seek dietetic advice rather than assuming all wholegrains are equivalent.
  • Wholegrains are not a reason to ignore total diet quality. In the cohort studies the comparison was between people who ate more and less wholegrain within otherwise different diets, so a wholegrain label on a high-sugar, high-salt product does not carry the same expectation.
  • If you have coeliac disease or a diagnosed wheat allergy, wholegrain wheat and barley and rye are not suitable; gluten-free wholegrains such as brown rice, oats labelled gluten-free, buckwheat and quinoa are the relevant options.

References

Whole grain consumption and risk of cardiovascular disease, cancer, and all cause and cause specific mortality: systematic review and dose-response meta-analysis of prospective studies.

Aune D, Keum N, Giovannucci E, Fadnes LT, Boffetta P, Greenwood DC, Tonstad S, Vatten LJ, Riboli E, Norat T · BMJ (Clinical research ed.) · 2016

Systematic review and dose-response meta-analysis of prospective studiesVerified from full text
Open original source

Whole-Grain Intake and Mortality from All Causes, Cardiovascular Disease, and Cancer: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies.

Benisi-Kohansal S, Saneei P, Salehi-Marzijarani M, Larijani B, Esmaillzadeh A · Advances in nutrition (Bethesda, Md.) · 2016

Systematic review and dose-response meta-analysis of prospective cohort studiesVerified from full text
Open original source

The Effect of Replacing Refined Grains with Whole Grains on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Clinical Recommendation

Marshall S, Petocz P, Duve E, Abbott K, Cassettari T, Blumfield M, Fayet-Moore F · Journal of the Academy of Nutrition and Dietetics · 2020

Systematic review and meta-analysis of randomized controlled trials with GRADE clinical recommendationVerified from abstract
Open original source

Whole grain and refined grain consumption and the risk of type 2 diabetes: a systematic review and dose-response meta-analysis of cohort studies.

Aune D, Norat T, Romundstad P, Vatten LJ · European journal of epidemiology · 2013

Systematic review and dose-response meta-analysis of cohort studiesVerified from abstract
Open original source

Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies.

Aune D, Chan DS, Lau R, Vieira R, Greenwood DC, Kampman E, Norat T · BMJ (Clinical research ed.) · 2011

Systematic review and dose-response meta-analysis of prospective observational studiesVerified from full text
Open original source

Whole grain consumption and human health: an umbrella review of observational studies.

Tieri M, Ghelfi F, Vitale M, Vetrani C, Marventano S, Lafranconi A, Godos J, Titta L, Gambera A, Alonzo E, Sciacca S, Riccardi G, Buscemi S, Del Rio D, Ray S, Galvano F, Beck E, Grosso G · International journal of food sciences and nutrition · 2020

Umbrella review of meta-analyses of observational studiesVerified from abstract
Open original source

Whole grain-rich diet reduces body weight and systemic low-grade inflammation without inducing major changes of the gut microbiome: a randomised cross-over trial

Roager HM, Vogt JK, Kristensen M, Hansen LBS, Ibrugger S, Maerkedahl RB, Bahl MI, Lind MV, Nielsen RL, Frokiaer H, Gobel RJ, Landberg R, Ross AB, Satokari R, Sorensen SJ, Sondertoft NB, Rasmussen SS, Raun KB, Holck J, Meyer AS, Licht TR · Gut · 2019

Randomised cross-over trialVerified from abstract
Open original source

Community

Discussion

Have you tried this? What helped or made it difficult?

Reader experiences are separate from the scientific evidence. Explore all discussions

No discussions yet.

Be the first to ask a question or share your experience.

Sign in to vote or join the discussion.

Related habits

Explore other habits in a shared category. Each has its own evidence and precautions.

Editorial history and review method

Revision 3 · Approved for publication · Codex (publication approval explicitly authorized by site owner; category migration)

Prepared and checked with AI. Publication approval does not imply independent expert review. Request a correction.

Audit correction pass (group 7). (1) marshall-2020-refined-grain-rct was added to the sourceIds of both outcomes. The verdict's '25 randomised trials lasting 2 to 16 weeks improved total cholesterol, LDL cholesterol, HbA1c and C-reactive protein' and the card summary's attributed conclusion ('insufficient evidence to recommend wholegrains over refined grains for preventing cardiovascular disease') previously had no cited source; they now cite the retrieved Marshall 2020 record (25 randomised trials included, 22 meta-analysed, interventions 2 to 16 weeks; whole-grain oats total cholesterol SMD -0.54, 95% CI -0.95 to -0.12 and LDL SMD -0.57, -0.84 to -0.31; whole grains all types HbA1c SMD -0.33, -0.61 to -0.04 and C-reactive protein SMD -0.22, -0.44 to -0.00), which was already in content/sources.json. (2) roager-2019-wholegrain-crossover was added to the type-2-diabetes-and-colorectal-cancer sourceIds and its counter-evidence written into that outcome's limitations and certaintyRationale: no significant change in glucose homeostasis and no major change in the faecal microbiome despite a compliance-verified 179 g/day wholegrain intake, with the body-weight reduction consistent with reduced energy intake. (3) The all-cause-and-cardiovascular-mortality outcome label was changed from 'Death from any cause and cardiovascular disease events' to 'Death from any cause and incident cardiovascular disease', because the pooled estimate it prints (RR 0.78) is explicitly for incident cardiovascular disease. (4) The review record's source count of seven now matches the record: five previously cited sources plus the two added here. No number changed — the audit verified every estimate against Aune 2016, Benisi-Kohansal 2016, Aune 2013, Aune 2011 and Tieri 2020 and found none wrong. A second reviewer must re-check: (1) that the two added sources are cited for claims they actually support rather than as decoration, and in particular that the Roager trial is not presented as a disease-outcome trial; (2) that no verified fact or effect estimate duplicates a claim in the fibre-intake or soluble-fibre-cholesterol entries; (3) that the prostate-cancer signal from the umbrella review stays in the limitations; and (4) the audit's open item — whether Aune 2016 and Benisi-Kohansal 2016 share contributing cohorts, since both pool prospective cohorts over overlapping periods and both report the same 90 g/day increment, in which case the phrase 'an independent synthesis' overstates their independence. Publication release 2026-10-04: site owner authorized a bounded AI audit and release of this exact revision. See docs/release-audit-2026-10-04.md for source-check findings and limits. No independent health-professional or peer review is claimed. Category migration 2026-10-04: removed the separate goals field; categories: Nutrition, Long-term health → Nutrition, Long-term health. Research assessments, sources, guidance, precautions, and evidence review dates are unchanged. This revision awaits publication approval; no new evidence review is claimed. Publication approval 2026-10-04: site owner explicitly accepted all current category-migration revisions for deployment and requested that remaining limitations be retained in docs/content-review-backlog.md. Approval applies to this exact content revision. No new evidence review, independent expert review, or clinical validation is claimed; existing precautions and disclosures remain in effect.